Summary
Probiodrug AG (Probiodrug) is a biopharmaceutical company that specializes in the research and development of therapies for Alzheimer’s disease. The company has three pipeline drug candidates, namely, PQ912, PBD-C06 and PQ1565. PQ912, a small molecule glutaminyl cyclase (QC) inhibitor, is the company’s lead drug candidate in Phase II clinical trials that inhibits QC-enzyme, which proved beneficial in Alzheimer’s in animal models. PBD-C06, a monoclonal antibody under evaluation, aims at clearing toxic pyroglutamate-Abeta (pGlu-Abeta) in the brain. PQ1565, the company’s second QC inhibitor, is in preclinical stage and demonstrated attractive drug-like properties. The company developed a therapeutic approach, dipeptidyl peptidase 4 (DP4) inhibitors, for the treatment of diabetes. Probiodrug is headquartered in Halle, Sachsen-Anhalt, Germany.
Probiodrug AG (PBD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Probiodrug AG, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Probiodrug AG, Medical Devices Deals, 2010 to YTD 2016 9
Probiodrug AG, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Probiodrug AG, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Probiodrug Secures US$19.5 Million In Series C Financing 11
Partnerships 14
Probiodrug Enters into Research Agreement with Paul-Flechsig-Institute 14
Probiodrug Enters Into Co-Development Agreement With VU University Medical Center 15
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 16
Licensing Agreements 17
QPS Austria Enters into Licensing Agreement with Probiodrug 17
Equity Offering 18
Probiodrug Raises USD14.7 Million in Private Placement of Shares 18
Probiodrug Completes IPO for USD29.6 Million 20
Asset Transactions 22
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 22
Probiodrug AG - Key Competitors 24
Key Employees 25
Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List of Tables
Probiodrug AG, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Probiodrug AG, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Probiodrug AG, Deals By Therapy Area, 2010 to YTD 2016 8
Probiodrug AG, Medical Devices Deals, 2010 to YTD 2016 9
Probiodrug AG, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Probiodrug Secures US$19.5 Million In Series C Financing 11
Probiodrug Enters into Research Agreement with Paul-Flechsig-Institute 14
Probiodrug Enters Into Co-Development Agreement With VU University Medical Center 15
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 16
QPS Austria Enters into Licensing Agreement with Probiodrug 17
Probiodrug Raises USD14.7 Million in Private Placement of Shares 18
Probiodrug Completes IPO for USD29.6 Million 20
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 22
Probiodrug AG, Key Competitors 24
Probiodrug AG, Key Employees 25
Probiodrug AG, Subsidiaries 26
List of Figures
Probiodrug AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Probiodrug AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Probiodrug AG, Medical Devices Deals, 2010 to YTD 2016 9